X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (202) 202
cardiac & cardiovascular systems (159) 159
male (154) 154
female (153) 153
middle aged (137) 137
aged (134) 134
abridged index medicus (120) 120
acute coronary syndromes (95) 95
heart attacks (84) 84
treatment outcome (82) 82
risk factors (76) 76
drug therapy (68) 68
mortality (66) 66
clopidogrel (63) 63
cardiovascular (62) 62
platelet aggregation inhibitors - therapeutic use (58) 58
ticlopidine - analogs & derivatives (58) 58
myocardial infarction (56) 56
heart attack (54) 54
peripheral vascular disease (53) 53
double-blind method (50) 50
care and treatment (49) 49
myocardial infarction - drug therapy (49) 49
percutaneous coronary intervention (46) 46
aspirin (45) 45
prasugrel hydrochloride (44) 44
acute coronary syndrome - drug therapy (43) 43
medicine, general & internal (43) 43
clinical trials (42) 42
acute coronary syndrome (41) 41
coronary heart disease (41) 41
patient outcomes (41) 41
cardiovascular disease (40) 40
myocardial infarction - mortality (40) 40
cardiac patients (39) 39
myocardial-infarction (39) 39
ticlopidine - therapeutic use (39) 39
cardiovascular diseases (38) 38
cardiology (37) 37
time factors (37) 37
outcomes (35) 35
risk (35) 35
drug therapy, combination (33) 33
internal medicine (33) 33
electrocardiography (32) 32
follow-up studies (32) 32
platelet aggregation inhibitors - administration & dosage (32) 32
prasugrel (32) 32
usage (32) 32
piperazines - therapeutic use (31) 31
stroke (31) 31
thiophenes - therapeutic use (31) 31
diabetes (30) 30
thrombosis (29) 29
clinical outcomes (28) 28
patients (28) 28
registries (27) 27
risk assessment (27) 27
analysis (26) 26
cholesterol (26) 26
heart failure (26) 26
hemorrhage - chemically induced (26) 26
antiplatelet therapy (25) 25
blood platelets (25) 25
diabetes mellitus (24) 24
dosage and administration (24) 24
dose-response relationship, drug (24) 24
health aspects (24) 24
research (24) 24
ticlopidine - administration & dosage (24) 24
aged, 80 and over (23) 23
cardiology and cardiovascular medicine (23) 23
coronary vessels (23) 23
prevention (23) 23
unstable angina (23) 23
artery-disease (22) 22
myocardial infarction - therapy (22) 22
safety (22) 22
adult (21) 21
intervention (21) 21
platelet aggregation inhibitors - adverse effects (21) 21
acute coronary syndrome - therapy (20) 20
anticoagulants (20) 20
myocardial infarction - prevention & control (20) 20
stent thrombosis (20) 20
stents (20) 20
therapy (20) 20
thiophenes - administration & dosage (20) 20
thrombolysis (20) 20
aspirin - therapeutic use (19) 19
association task-force (19) 19
cerebral infarction (19) 19
events (19) 19
hematology (19) 19
incidence (19) 19
myocardial infarction - epidemiology (19) 19
prognosis (19) 19
angioplasty, balloon, coronary (18) 18
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (18) 18
piperazines - administration & dosage (18) 18
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
MORTALITY | 2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Life Sciences | Food and Nutrition | Animal biology | Cellular Biology | Pharmaceutical sciences | Cardiovascular Diseases | drug therapy | Benzhydryl Compounds | complications | Sodium-Glucose Transporter 2 Inhibitors | Hospitalization | prevention & control | Klinisk medicin | Diabetes Mellitus | etiology | Clinical Medicine | epidemiology | statistics & numerical data | adverse effects | mortality | Type 2 | Heart Failure | therapeutic use | Glucosides
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9694, pp. 989 - 997
Summary Background Proton-pump inhibitors (PPIs) are often prescribed in combination with thienopyridines. Conflicting data exist as to whether PPIs diminish... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | PLATELET-AGGREGATION | OF-FUNCTION POLYMORPHISM | OMEPRAZOLE | THROMBOLYSIS | ACUTE CORONARY SYNDROMES | OUTCOMES | ANTIPLATELET ACTION | ATORVASTATIN | Multivariate Analysis | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Thiophenes - adverse effects | Ticlopidine - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Pyridines - adverse effects | Drug Interactions | Ticlopidine - adverse effects | Cardiovascular Diseases - epidemiology | Female | Platelet Aggregation - drug effects | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Proton Pump Inhibitors - adverse effects | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Piperazines - therapeutic use | Proton Pump Inhibitors - therapeutic use | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Randomized Controlled Trials as Topic | Acute Coronary Syndrome - drug therapy | Aged | Complications and side effects | Clopidogrel | Proton pump inhibitors | Dosage and administration | Pharmacology | Research | Properties | Studies | Data collection | Data analysis | Drug therapy | Acute coronary syndromes | Clinical outcomes | Cytochrome | Myocardial infarction | Cerebral infarction | Stroke | Funding | Clinical trials | Platelet aggregation | Agglomeration | Patients | Evidence-based medicine | Randomization | Blood platelets | Infarction | Inhibition | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9892, pp. 605 - 613
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 18, pp. 1713 - 1722
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 373, Issue 9665, pp. 723 - 731
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 15, pp. 1404 - 1413
Patients with atherosclerotic vascular disease were randomly assigned to receive the thrombin antagonist vorapaxar or placebo. Vorapaxar reduced the rate of... 
ATOPAXAR | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | EFFICACY | SAFETY | TOLERABILITY | DOUBLE-BLIND | PRASUGREL | LESSONS | ANTAGONISTS | ASPIRIN | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Risk | Secondary Prevention | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Hemorrhage - epidemiology | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Peripheral Arterial Disease - drug therapy | Stroke - drug therapy | Lactones - adverse effects | Lactones - therapeutic use | Retreatment | Myocardial Infarction - drug therapy | Brain Ischemia - drug therapy | Intracranial Hemorrhages - chemically induced | Intracranial Hemorrhages - epidemiology | Aged | Hemorrhage - chemically induced | Prevention | Drugs | Aggregation | Dose-response relationship (Biochemistry) | Atheroembolism | Blood platelets | Atherosclerosis | Product/Service Evaluations | Dosage and administration | Drug therapy | Myocardial infarction | Cerebral infarction | Stroke | Aspirin | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Hemorrhage | Patients | Bleeding | Disease prevention | Ischemia | Arteriosclerosis | Death | Cardiovascular diseases | Health risk assessment | Computer Science | Medical Imaging
Journal Article
Journal Article